Literature DB >> 27320166

Global Foot-and-Mouth Disease Research Update and Gap Analysis: 5 - Biotherapeutics and Disinfectants.

L Robinson1, T J D Knight-Jones2, B Charleston3, L L Rodriguez4, C G Gay5, K J Sumption6, W Vosloo7.   

Abstract

We assessed knowledge gaps in foot-and-mouth disease (FMD) research. Findings are reported in a series of papers, and in this article, we consider biotherapeutics and disinfectants. The study took the form of a literature review (2011-2015) combined with research updates collected in 2014 from 33 institutes from across the world. Findings were used to identify priority areas for future FMD research. While vaccines will remain the key immunological intervention used against FMD virus (FMDV) for the foreseeable future, it takes a few days for the immune system to respond to vaccination. In an outbreak situation, protection could potentially be provided during this period by the application of rapid, short-acting biotherapeutics, aiming either to stimulate a non-specific antiviral state in the animal or to specifically inhibit a part of the viral life cycle. Certain antiviral cytokines have been shown to promote rapid protection against FMD; however, the effects of different immune-modulators appear to vary across species in ways and for reasons that are not yet understood. Major barriers to the effective incorporation of biotherapeutics into control strategies are cost, limited understanding of their effect on subsequent immune responses to vaccines and uncertainty about their potential impact if used for disease containment. Recent research has highlighted the importance of environmental contamination in FMDV transmission. Effective disinfectants for FMDV have long been available, but research is being conducted to further develop methods for quantitatively evaluating their performance under field, or near-field, conditions. During outbreaks in South Korea in 2010 there was public concern about potential environmental contamination after the mass use of disinfectant and mass burial of culled stock; this should be considered during outbreak contingency planning.
© 2016 Blackwell Verlag GmbH.

Entities:  

Keywords:  FMD; Foot-and-mouth disease; biotherapeutics; disinfectants; gap analysis

Mesh:

Substances:

Year:  2016        PMID: 27320166     DOI: 10.1111/tbed.12519

Source DB:  PubMed          Journal:  Transbound Emerg Dis        ISSN: 1865-1674            Impact factor:   5.005


  7 in total

1.  Ribavirin as a curative and prophylactic agent against foot and mouth disease virus infection in C57BL/6 suckling and adult mice model.

Authors:  Patel Nikunjkumar; Ramasamy Periyasamy Tamil Selvan; Veerakyathappa Bhanuprakash
Journal:  Virusdisease       Date:  2021-10-20

2.  Amber codon is genetically unstable in generation of premature termination codon (PTC)-harbouring Foot-and-mouth disease virus (FMDV) via genetic code expansion.

Authors:  Rongzeng Hao; Kun Ma; Yi Ru; Dan Li; Gaoyuan Song; Bingzhou Lu; Huanan Liu; Yajun Li; Jiaoyan Zhang; Chunping Wu; Guicai Zhang; Haitao Hu; Jianxun Luo; Haixue Zheng
Journal:  RNA Biol       Date:  2021-04-14       Impact factor: 4.652

Review 3.  Molecular Mechanisms of Foot-and-Mouth Disease Virus Targeting the Host Antiviral Response.

Authors:  Miguel Rodríguez Pulido; Margarita Sáiz
Journal:  Front Cell Infect Microbiol       Date:  2017-06-13       Impact factor: 5.293

4.  Innate immune sensor LGP2 is cleaved by the Leader protease of foot-and-mouth disease virus.

Authors:  Miguel Rodríguez Pulido; María Teresa Sánchez-Aparicio; Encarnación Martínez-Salas; Adolfo García-Sastre; Francisco Sobrino; Margarita Sáiz
Journal:  PLoS Pathog       Date:  2018-06-29       Impact factor: 6.823

5.  The DEAD-Box RNA Helicase DDX1 Interacts with the Viral Protein 3D and Inhibits Foot-and-Mouth Disease Virus Replication.

Authors:  Qiao Xue; Huisheng Liu; Qiaoying Zeng; Haixue Zheng; Qinghong Xue; Xuepeng Cai
Journal:  Virol Sin       Date:  2019-07-29       Impact factor: 4.327

6.  The HSP70-fused foot-and-mouth disease epitope elicits cellular and humoral immunity and drives broad-spectrum protective efficacy.

Authors:  Hyundong Jo; Bong Yoon Kim; So Hui Park; Hyun Mi Kim; Sung Ho Shin; Seong Yun Hwang; Su-Mi Kim; Byounghan Kim; Jong-Hyeon Park; Min Ja Lee
Journal:  NPJ Vaccines       Date:  2021-03-26       Impact factor: 7.344

7.  RNAi combining Sleeping Beauty transposon system inhibits ex vivo expression of foot-and-mouth disease virus VP1 in transgenic sheep cells.

Authors:  Shoulong Deng; Guangdong Li; Kun Yu; Xiuzhi Tian; Feng Wang; Wenting Li; Wuqi Jiang; Pengyun Ji; Hongbing Han; Juncai Fu; Xiaosheng Zhang; Jinlong Zhang; Yixun Liu; Zhengxing Lian; Guoshi Liu
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.